Literature DB >> 30470398

Low-Grade Glioma Radiotherapy Treatment and Trials.

Tony J C Wang1, Minesh P Mehta2.   

Abstract

Low-grade gliomas represent an important class of primary brain tumors. They account for approximately 20% of primary brain tumors and typically present in the fourth decade of life. Standard management gliomas involves observation, surgery, chemotherapy, and/or radiotherapy. Treatment decisions are based on many factors including prognostic molecular markers, potential benefits of increased progression-free survival, and potential long-term treatment complications. Recent studies have improved our understanding regarding therapeutic interventions. This review provides an overview of low-grade glioma and discusses the roles of radiation therapy. We discuss advances in techniques and recent and ongoing radiation therapy-related clinical trials for low-grade gliomas.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Low-grade glioma; Radiotherapy; Trials

Mesh:

Year:  2018        PMID: 30470398     DOI: 10.1016/j.nec.2018.08.008

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  25 in total

Review 1.  Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.

Authors:  Mohaddeseh Hedayat; Reza Jafari; Naime Majidi Zolbanin
Journal:  Clin Exp Med       Date:  2022-02-16       Impact factor: 3.984

2.  Construction of a Risk Model to Predict the Prognosis and Immunotherapy of Low-Grade Glioma Ground on 7 Ferroptosis-Related Genes.

Authors:  Liwei Sun; Bing Li; Bin Wang; Jinduo Li; Jing Li
Journal:  Int J Gen Med       Date:  2022-05-05

3.  Radiotherapy in adult low-grade glioma: nationwide trends in treatment and outcomes.

Authors:  R S Nunna; S Khalid; J S Ryoo; A Sethi; R W Byrne; A I Mehta
Journal:  Clin Transl Oncol       Date:  2020-07-20       Impact factor: 3.405

4.  Development and Validation of a Radiosensitivity Prediction Model for Lower Grade Glioma Based on Spike-and-Slab Lasso.

Authors:  Zixuan Du; Shang Cai; Derui Yan; Huijun Li; Xinyan Zhang; Wei Yang; Jianping Cao; Nengjun Yi; Zaixiang Tang
Journal:  Front Oncol       Date:  2021-07-30       Impact factor: 6.244

5.  Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas.

Authors:  Derui Yan; Qi Zhao; Zixuan Du; Huijun Li; Ruirui Geng; Wei Yang; Xinyan Zhang; Jianping Cao; Nengjun Yi; Juying Zhou; Zaixiang Tang
Journal:  Sci Rep       Date:  2022-04-23       Impact factor: 4.996

6.  A three-lncRNA signature predicts clinical outcomes in low-grade glioma patients after radiotherapy.

Authors:  Wanzun Lin; Zongwei Huang; Yanyan Xu; Xiaochuan Chen; Ting Chen; Yuling Ye; Jianming Ding; Zhangjie Chen; Long Chen; Xianxin Qiu; Sufang Qiu
Journal:  Aging (Albany NY)       Date:  2020-05-26       Impact factor: 5.682

Review 7.  From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.

Authors:  Xueyuan Sun; Sevin Turcan
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

Review 8.  The Roles Played by Long Non-Coding RNAs in Glioma Resistance.

Authors:  Yeonsoo Chae; Jungwook Roh; Wanyeon Kim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

9.  Identification and Validation of an 11-Ferroptosis Related Gene Signature and Its Correlation With Immune Checkpoint Molecules in Glioma.

Authors:  Zhuohui Chen; Tong Wu; Zhouyi Yan; Mengqi Zhang
Journal:  Front Cell Dev Biol       Date:  2021-06-23

10.  Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.

Authors:  Sanjay Dhawan; Chirag G Patil; Clark Chen; Andrew S Venteicher
Journal:  Cochrane Database Syst Rev       Date:  2020-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.